Jolly Pharmaceuticals released its performance for the first three quarters, with a net profit attributable to the parent company of 510 million yuan, an increase of 21.00%
I'm PortAI, I can summarize articles.
According to the Zhitong Finance APP, Jolly Pharmaceuticals released its third-quarter report for 2025. The company's operating revenue for the first three quarters was 2.28 billion yuan, a year-on-year increase of 11.48%. The net profit attributable to shareholders of the listed company was 510 million yuan, a year-on-year increase of 21.00%. The net profit attributable to shareholders of the listed company after deducting non-recurring gains and losses was 509 million yuan, a year-on-year increase of 22.51%. The basic earnings per share were 0.7271 yuan
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Zhitong The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments